Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.51
BCR's Cash-to-Debt is ranked lower than
67% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BCR: 0.51 )
Ranked among companies with meaningful Cash-to-Debt only.
BCR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.62 Max: N/A
Current: 0.51
Equity-to-Asset 0.32
BCR's Equity-to-Asset is ranked lower than
82% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BCR: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
BCR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.54 Max: 0.77
Current: 0.32
0.28
0.77
Interest Coverage 16.51
BCR's Interest Coverage is ranked lower than
62% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. BCR: 16.51 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s Interest Coverage Range Over the Past 10 Years
Min: 15.05  Med: 23.74 Max: 60.49
Current: 16.51
15.05
60.49
Piotroski F-Score: 8
Altman Z-Score: 4.98
Beneish M-Score: -2.40
WACC vs ROIC
4.76%
32.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.47
BCR's Operating Margin % is ranked higher than
93% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. BCR: 25.47 )
Ranked among companies with meaningful Operating Margin % only.
BCR' s Operating Margin % Range Over the Past 10 Years
Min: 18.91  Med: 25.4 Max: 39.79
Current: 25.47
18.91
39.79
Net Margin % 15.70
BCR's Net Margin % is ranked higher than
82% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. BCR: 15.70 )
Ranked among companies with meaningful Net Margin % only.
BCR' s Net Margin % Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 15.7
3.96
22.62
ROE % 36.19
BCR's ROE % is ranked higher than
95% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. BCR: 36.19 )
Ranked among companies with meaningful ROE % only.
BCR' s ROE % Range Over the Past 10 Years
Min: 8.19  Med: 22.49 Max: 36.19
Current: 36.19
8.19
36.19
ROA % 11.28
BCR's ROA % is ranked higher than
83% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. BCR: 11.28 )
Ranked among companies with meaningful ROA % only.
BCR' s ROA % Range Over the Past 10 Years
Min: 2.73  Med: 14.07 Max: 17.1
Current: 11.28
2.73
17.1
ROC (Joel Greenblatt) % 86.69
BCR's ROC (Joel Greenblatt) % is ranked higher than
95% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. BCR: 86.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.37  Med: 81.73 Max: 148.85
Current: 86.69
53.37
148.85
3-Year Revenue Growth Rate 9.30
BCR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BCR: 9.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.7  Med: 9.1 Max: 13.9
Current: 9.3
-0.7
13.9
3-Year EBITDA Growth Rate -10.70
BCR's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. BCR: -10.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.9  Med: 8.6 Max: 41.1
Current: -10.7
-18.9
41.1
3-Year EPS without NRI Growth Rate -5.70
BCR's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BCR: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: 10.1 Max: 43.4
Current: -5.7
-34
43.4
GuruFocus has detected 5 Warning Signs with C.R. Bard Inc $BCR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BCR Guru Trades in Q2 2016

Louis Moore Bacon 904 sh (New)
Tom Gayner 9,000 sh (unchged)
Jeremy Grantham Sold Out
Yacktman Focused Fund Sold Out
Pioneer Investments 289,061 sh (-0.05%)
Ray Dalio 20,815 sh (-10.72%)
Jim Simons 1,063,200 sh (-21.55%)
Yacktman Fund 650,000 sh (-27.78%)
Donald Yacktman 806,300 sh (-36.85%)
Joel Greenblatt 5,582 sh (-96.30%)
Paul Tudor Jones 1,100 sh (-99.51%)
» More
Q3 2016

BCR Guru Trades in Q3 2016

Jeremy Grantham 98,050 sh (New)
Steven Cohen 229,200 sh (New)
Paul Tudor Jones 126,800 sh (+11427.27%)
Louis Moore Bacon 2,426 sh (+168.36%)
Tom Gayner Sold Out
Pioneer Investments 271,837 sh (-5.96%)
Donald Yacktman 738,964 sh (-8.35%)
Yacktman Fund 550,000 sh (-15.38%)
Jim Simons 797,200 sh (-25.02%)
Joel Greenblatt 3,760 sh (-32.64%)
Ray Dalio 6,915 sh (-66.78%)
» More
Q4 2016

BCR Guru Trades in Q4 2016

George Soros 900 sh (New)
Joel Greenblatt 50,845 sh (+1252.26%)
Steven Cohen 382,200 sh (+66.75%)
Yacktman Fund 550,000 sh (unchged)
Ray Dalio Sold Out
Donald Yacktman 723,901 sh (-2.04%)
Jeremy Grantham 95,867 sh (-2.23%)
Jim Simons 509,400 sh (-36.10%)
Paul Tudor Jones 75,000 sh (-40.85%)
Pioneer Investments 31,481 sh (-88.42%)
» More
Q1 2017

BCR Guru Trades in Q1 2017

Yacktman Fund 350,000 sh (-36.36%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:CLPBY, NAS:ILMN, OTCPK:ESLOY, NAS:XRAY, NYSE:BAX, NYSE:WAT, NYSE:MTD, OTCPK:TRUMY, OTCPK:OCPNY, NAS:HOLX, NYSE:COO, NYSE:RMD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, OTCPK:GNGBF, NYSE:HRC, NYSE:BDX, NYSE:CMD, NAS:ICUI » details
Traded in other countries:BR6.Germany,
Headquarter Location:USA
C.R. Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard designs, manufactures, and markets a wide range of medical, diagnostic, and surgical devices that are primarily intended for one-time use. The firm enjoys a sizable footprint in key therapeutic areas, including urology, oncology, peripheral vascular solutions, soft tissue surgery, breast biopsy and reconstruction. Sales to foreign countries account for approximately one third of total revenue.

Guru Investment Theses on C.R. Bard Inc

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

Yacktman Fund Sells Viacom, Oracle, Microsoft The fund's largest 1st-quarter trades
The Yacktman Fund (Trades, Portfolio) seeks long-term capital appreciation by investing in common stocks of U.S. companies of any size. During the first quarter, the fund sold shares in the following stocks: Read more...
Tom Gayner Sells 5 Holdings, Reduces 1 Other An overview of the guru's 3rd quarter sales
Tom Gayner (Trades, Portfolio) is co-CEO of Markel Corp., and president and chief investment officer of Markel-Gayner Asset Management. During the third quarter, the guru reduced or exited the following holdings: Read more...
Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Insider buy
Timothy Ring (Insider Trades), CEO and Chairman of C.R. Bard Inc. (BCR), sold 92,293 shares of the company on Sept. 28, 2016. The average price per share was $227.81, for a total transaction of $21,025,268. C.R. Bard, a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in vascular, urology, oncology and surgical specialty products, has a market cap of $16.47 billion. Read more...
Insider Trades: C.R. Bard, NVIDIA and Alphabet Largest insider trades of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the "Insiders" tab and changing the settings for All Insider Buys to “200,000sh+” duration to "September 2016” and “September 2016” and All Insider Sales to “$5,000,000+”. Read more...
Yacktman Fund Hopeful After Second Quarter Report Fund comments on PepsiCo, Fox
The AMG Yacktman Fund (Trades, Portfolio) (YACKX) gave their second quarter update on July 27. Joe Maccone from Affiliated Managers Group Fund (AMG) moderated the meeting. Stephen Yacktman and Jason Subotky, the portfolio managers at Yacktman Asset Management, gave their views on the portfolio’s performance as well as discussed their major stock purchases and sales. Read more...
The Yacktman Focused Fund Sells Out of C.R. Bard Inc. C.R. Bard reached its 52-week high during the second quarter
During the second quarter, the Yacktman (Trades, Portfolio) Focused Fund sold out its remaining 140,000 shares of C.R Bard (NYSE:BCR) at at an average price of $216.98. The Yacktman (Trades, Portfolio) Focused Fund saw a 66% increase in its investment in C.R. Bard Inc. since the first quarter of 2011. Read more...
5 Companies Achieve 52-Week Highs C.R. Bard, Tim Hortons, Thermo Fisher, Fiserv, Molson Coors reach landmarks
According to GuruFocus list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.12
BCR's PE Ratio is ranked lower than
60% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. BCR: 39.12 )
Ranked among companies with meaningful PE Ratio only.
BCR' s PE Ratio Range Over the Past 10 Years
Min: 14.25  Med: 24.43 Max: 154.75
Current: 39.12
14.25
154.75
Forward PE Ratio 26.39
BCR's Forward PE Ratio is ranked higher than
69% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. BCR: 26.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.12
BCR's PE Ratio without NRI is ranked lower than
60% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. BCR: 39.12 )
Ranked among companies with meaningful PE Ratio without NRI only.
BCR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.25  Med: 24.14 Max: 154.75
Current: 39.12
14.25
154.75
Price-to-Owner-Earnings 95.91
BCR's Price-to-Owner-Earnings is ranked lower than
88% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. BCR: 95.91 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BCR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.25  Med: 25.32 Max: 434.61
Current: 95.91
12.25
434.61
PB Ratio 13.30
BCR's PB Ratio is ranked lower than
91% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. BCR: 13.30 )
Ranked among companies with meaningful PB Ratio only.
BCR' s PB Ratio Range Over the Past 10 Years
Min: 3.22  Med: 4.75 Max: 13.3
Current: 13.3
3.22
13.3
PS Ratio 6.11
BCR's PS Ratio is ranked lower than
64% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. BCR: 6.11 )
Ranked among companies with meaningful PS Ratio only.
BCR' s PS Ratio Range Over the Past 10 Years
Min: 2.56  Med: 3.64 Max: 6.11
Current: 6.11
2.56
6.11
Price-to-Free-Cash-Flow 44.71
BCR's Price-to-Free-Cash-Flow is ranked lower than
71% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. BCR: 44.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BCR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.1  Med: 17.66 Max: 49.36
Current: 44.71
10.1
49.36
Price-to-Operating-Cash-Flow 37.26
BCR's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. BCR: 37.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BCR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.09  Med: 15 Max: 40.02
Current: 37.26
9.09
40.02
EV-to-EBIT 29.64
BCR's EV-to-EBIT is ranked lower than
58% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. BCR: 29.64 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 15.9 Max: 49.4
Current: 29.64
8
49.4
EV-to-EBITDA 23.32
BCR's EV-to-EBITDA is ranked lower than
60% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. BCR: 23.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 13.4 Max: 31.5
Current: 23.32
7.2
31.5
PEG Ratio 17.00
BCR's PEG Ratio is ranked lower than
100% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. BCR: 17.00 )
Ranked among companies with meaningful PEG Ratio only.
BCR' s PEG Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.62 Max: 39.28
Current: 17
0.94
39.28
Shiller PE Ratio 57.52
BCR's Shiller PE Ratio is ranked lower than
51% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. BCR: 57.52 )
Ranked among companies with meaningful Shiller PE Ratio only.
BCR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.36  Med: 31.48 Max: 57.52
Current: 57.52
23.36
57.52
Current Ratio 1.48
BCR's Current Ratio is ranked lower than
61% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. BCR: 1.48 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.22 Max: 5.88
Current: 1.48
1.14
5.88
Quick Ratio 1.16
BCR's Quick Ratio is ranked lower than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. BCR: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.66 Max: 4.72
Current: 1.16
0.62
4.72
Days Inventory 123.52
BCR's Days Inventory is ranked higher than
53% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. BCR: 123.52 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 99.01  Med: 105.62 Max: 123.52
Current: 123.52
99.01
123.52
Days Sales Outstanding 43.46
BCR's Days Sales Outstanding is ranked higher than
78% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. BCR: 43.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.46  Med: 59 Max: 63.66
Current: 43.46
43.46
63.66
Days Payable 26.49
BCR's Days Payable is ranked lower than
89% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. BCR: 26.49 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.88 Max: 28.74
Current: 26.49
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.34
BCR's Dividend Yield % is ranked lower than
88% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BCR: 0.34 )
Ranked among companies with meaningful Dividend Yield % only.
BCR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.33  Med: 0.68 Max: 0.9
Current: 0.34
0.33
0.9
Dividend Payout Ratio 0.13
BCR's Dividend Payout Ratio is ranked higher than
82% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BCR: 0.13 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BCR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.15 Max: 0.52
Current: 0.13
0.1
0.52
3-Year Dividend Growth Rate 6.80
BCR's 3-Year Dividend Growth Rate is ranked lower than
63% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. BCR: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BCR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 24.1
Current: 6.8
3.2
24.1
Forward Dividend Yield % 0.34
BCR's Forward Dividend Yield % is ranked lower than
92% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. BCR: 0.34 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.45
BCR's 5-Year Yield-on-Cost % is ranked lower than
85% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. BCR: 0.45 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BCR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.44  Med: 0.91 Max: 1.2
Current: 0.45
0.44
1.2
3-Year Average Share Buyback Ratio 1.70
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. BCR: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3  Med: 1.6 Max: 5.3
Current: 1.7
-3
5.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.80
BCR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
56% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. BCR: 2.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BCR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.58 Max: 2.87
Current: 2.8
0.91
2.87
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.66
BCR's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
78% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. BCR: 3.66 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.68
BCR's Price-to-Median-PS-Value is ranked lower than
66% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. BCR: 1.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.71 Max: 1.68
Current: 1.68
0.26
1.68
Earnings Yield (Greenblatt) % 3.37
BCR's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. BCR: 3.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 6.3 Max: 12.5
Current: 3.37
2
12.5
Forward Rate of Return (Yacktman) % 4.92
BCR's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. BCR: 4.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BCR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.9  Med: 17.3 Max: 22.8
Current: 4.92
4.9
22.8

More Statistics

Revenue (TTM) (Mil) $3,779
EPS (TTM) $ 7.86
Beta0.44
Short Percentage of Float2.04%
52-Week Range $203.63 - 307.88
Shares Outstanding (Mil)72.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,905 4,134 4,219
EPS ($) 11.66 8.51 13.93
EPS without NRI ($) 11.66 8.51 13.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.19%
Dividends per Share ($) 1.05 1.11 1.34
» More Articles for BCR

Headlines

Articles On GuruFocus.com
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R Apr 27 2017 
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best Int Apr 25 2017 
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investi Apr 25 2017 
Harwood Feffer LLP Announces Investigation of C. R. Bard, Inc. Apr 24 2017 
Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of C.R. Bard, Inc Apr 23 2017 
BD Announces Appointment Of Tom Polen As President Apr 23 2017 
BD To Acquire Bard For $24 Billion Apr 23 2017 
Tom Gayner Sells 5 Holdings, Reduces 1 Other Dec 22 2016 
Dividend Aristocrats in Focus Part 25: CR Bard Nov 01 2016 
Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 92,293 Shares of the Company on Sept. 28 Oct 01 2016 

More From Other Websites
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of C.R. Bard, Inc.... Apr 30 2017
Five CNBC IQ 100 components are hitting lifetime highs Apr 28 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C.... Apr 27 2017
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : May 01st, 2017 (record date) : By the... Apr 27 2017
How BD-Bard Acquisition Will Strengthen International Presence Apr 27 2017
3 Best Performing Stocks of April Apr 27 2017
How the BD-Bard Deal Will Create Shareholder Value Apr 27 2017
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of C.R. Bard, Inc.... Apr 26 2017
C.R. Bard’s Business Profile and the BD-Bard Deal Rationale Apr 26 2017
A Look at BD’s Deal Rationale in Its C.R. Bard Acquisition Apr 26 2017
Medical Device Maker Bolts Higher On Earnings In Massive Volume Apr 26 2017
BD to Acquire C.R. Bard: Deal Highlights and Market Reaction Apr 26 2017
C. R. Bard Stock Trades Ex-Dividend Thursday Apr 25 2017
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best... Apr 25 2017
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Apr 25 2017
Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More Apr 25 2017
Blog Coverage Becton, Dickinson and C. R. Bard Set to Merge in a $24 Billion Deal Apr 25 2017
[$$] Don’t Succumb to Sticker Shock on Becton Dickinson Deal Apr 24 2017
Tax cuts not driving this rally Apr 24 2017
Cramer: Trump tax cuts are not the driving force behind t... Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)